For decades, ultrasound has been used to image organs such as the heart and kidneys, check blood flow, monitor the development of fetuses, reduce pain and even break up kidney stones.
Now, a Norwegian biotech company called Phoenix Solutions AS is working with the Translational Genomics Research Institute (TGen), a Phoenix, Arizona-based biomedical research facility, to test the use of these pulsed sound waves to direct and focus cancer drug therapies.
In laboratory tests, TGen will help analyze the effectiveness of a technology called Acoustic Cluster Therapy (ACT), a unique approach to targeting cancer cells by concentrating the delivery of chemotherapies, making them more effective and potentially reducing their toxicity.
Humanscan Co. Ltd., a South Korean manufacture of ultrasound diagnostic imaging, is developing clinically applicable hardware optimized for ACT, which TGen will then validate.
Phoenix Solutions is using funding from Innovation Norway to conduct this research in advance of pancreatic cancer clinical trials planned later this year.
“We are very pleased to receive this grant, which will enable us to develop and validate an optimal ultrasound platform for clinical use of ACT. In their respective fields, Humanscan and TGen both represent the cutting edge of science, and we are confident this will contribute to the clinical success of our program,” said Dr. Per Sontum, CEO of Phoenix Solutions.
TGen is a world leader in the development of novel therapeutics for the treatment of pancreatic cancer. The TGen team led the clinical development of one of the current standard-of-care regimens for this disease — nab-paclitaxel plus gemcitabine. TGen currently is involved in 13 pancreatic cancer clinical programs.
“We are pleased that this research program has become a reality, and look forward to working with ACT. The concept represents a novel approach to targeted drug delivery and looks very promising,” said Dr. Haiyong Han, a Professor in TGen’s Molecular Medicine Division and head of the Basic Research Unit in TGen’s Pancreatic Cancer Program.
Among the advantages of ultrasound technology: it is generally painless; non-invasive; does not require needles, injections or incisions; and patients are not exposed to ionizing radiation, making the procedure safer than diagnostic techniques such as X-rays and CT scans.
Humanscan CEO Sungmin Rhim said, “We are excited to enter into this collaboration with Phoenix (Solutions) and participate in the development of ACT. Ultrasound mediated, targeted drug delivery is an emerging therapy approach with great potential and we are delighted to be in the forefront of this development.”
Phoenix Solutions also is considering this technology for use in addressing other types of cancer, including: liver, prostate and triple-negative breast cancer; and other diseases, including those involving inflammation and the central nervous system.
The Latest on: Cancer drug delivery
via Google News
The Latest on: Cancer drug delivery
- Researchers develop new platform that recreates cancer in a dish to quickly determine the best bacterial therapy on April 17, 2019 at 2:07 pm
They discovered a potent therapy for colon cancer, using a novel bacterial toxin, theta toxin, combined with an optimal drug delivery genetic circuit in attenuated bacteria Salmonella Typhimurium. […]
- Boehringer Ingelheim, PureTech to Partner on Cancer Immunotherapies on April 17, 2019 at 7:30 am
and To design nanomaterials to better target drug delivery to a range of diseases, including cancer. Promise Beyond Cancer The targeting approach developed by Porter’s lab can potentially be applied ... […]
- Healthcare Companies Search for New Ways to Oppose the Spread of Cancer on April 17, 2019 at 6:00 am
... to use NanoSmart's Anti-Nuclear Antibody (ANA)-targeted drug delivery technologies to develop and commercialize chemotherapy drug formulations for veterinary oncology. The National Cancer ... […]
- Carriers deliver controllable cancer chemotherapy on April 17, 2019 at 5:49 am
Cancer kills more than half a million men ... "The challenge is to design and synthesize a drug delivery system that is sensitive to both tumor-specific internal stimuli like pH and external ... […]
- Drug Delivery in Cancer Market 2019 Global Trends, Market Share, Industry Size, Growth, Opportunities and Forecast to 2024 on April 17, 2019 at 4:00 am
WiseGuyReports.com adds “Drug Delivery in Cancer Market 2019 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2024” reports to its database. This ... […]
- Global Drug Delivery in Cancer Industry Analysis 2019, Market Growth, Trends, Opportunities Forecast To 2024 on April 17, 2019 at 3:56 am
WiseGuyReports.com adds “Drug Delivery in Cancer Market 2019 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2024” reports to its database. This report focuses on the ... […]
- Drug Delivery Technology Market 2016 Industry Overview, Growth Analysis, Regional Demand and Growth Till 2026: Future Market Insights on April 16, 2019 at 8:25 pm
Drug Delivery Technology Market: Drivers & Restraints Growing incidence of chronic diseases such as cardiovascular diseases, diabetes, and cancer, technological advancement, innovation, the growing ... […]
- Injectable Drug Delivery Market Poised to Register a Growth of US $32,136.9 Mn by 2028 on April 15, 2019 at 8:14 pm
The market for injectable drug delivery is primarily driven by increasing prevalence of chronic diseases such as cancer, rheumatoid arthritis and diabetes. This press release was orginally distributed ... […]
- Scientists compare methods of drug delivery to malignant tumors on April 9, 2019 at 6:18 am
has analyzed available methods of targeted drug delivery to malignant tumors. Individual approaches to cancer therapy limit the influence of drugs on healthy tissues and reduce side effects. […]
via Bing News